anti-gremlin-1 monoclonal antibody UCB6114

A monoclonal antibody directed against gremlin-1 (GREM1; Drm), with potential antineoplastic activity. Upon administration, anti-gremlin-1 antibody UCB6114 specifically targets and binds to gremlin-1, thereby neutralizing Gremlin-1. This may block the gremlin-1-mediated inhibition of bone morphogenetic protein (BMP) signaling pathways, and may lead to the inhibition of tumor cell growth and proliferation. Gremlin-1, a BMP antagonist that is overexpressed in a variety of cancer cell types, is involved in cancer cell growth and proliferation as well as tissue fibrosis.